Neurocrine Biosciences, Inc.
NBIX
$152.72
$1.901.26%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 959.00M | 814.50M | 805.50M | 794.90M | 687.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 959.00M | 814.50M | 805.50M | 794.90M | 687.50M |
| Cost of Revenue | 346.70M | 310.00M | 275.80M | 264.00M | 254.60M |
| Gross Profit | 612.30M | 504.50M | 529.70M | 530.90M | 432.90M |
| SG&A Expenses | 383.10M | 318.50M | 302.50M | 291.60M | 286.30M |
| Depreciation & Amortization | 16.40M | -- | -- | -- | 1.00M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 746.20M | 628.50M | 578.30M | 555.60M | 541.90M |
| Operating Income | 212.80M | 186.00M | 227.20M | 239.30M | 145.60M |
| Income Before Tax | 162.20M | 246.80M | 239.40M | 291.80M | 159.50M |
| Income Tax Expenses | 17.80M | 48.90M | 85.70M | 82.30M | 52.00M |
| Earnings from Continuing Operations | 144.40M | 197.90M | 153.70M | 209.50M | 107.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 144.40M | 197.90M | 153.70M | 209.50M | 107.50M |
| EBIT | 212.80M | 186.00M | 227.20M | 239.30M | 145.60M |
| EBITDA | 237.60M | 193.30M | 234.70M | 247.00M | 152.90M |
| EPS Basic | 1.43 | 1.97 | 1.54 | 2.11 | 1.09 |
| Normalized Basic EPS | 1.38 | 1.33 | 1.58 | 1.64 | 1.05 |
| EPS Diluted | 1.39 | 1.91 | 1.48 | 2.04 | 1.06 |
| Normalized Diluted EPS | 1.33 | 1.29 | 1.52 | 1.59 | 1.03 |
| Average Basic Shares Outstanding | 101.00M | 100.50M | 99.90M | 99.40M | 99.00M |
| Average Diluted Shares Outstanding | 104.20M | 103.40M | 103.70M | 102.50M | 101.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |